This is the authors' abstract. We don't add key points for this paper.
// Gilli Galore-Haskel 1, * , Erez N. Baruch 1, 2, * , Amy L. Berg 1 , Iris Barshack 3, 4 , Itzhak Zilinsky 4, 5 , Camila Avivi 3 , Michal J. Besser 1, 2 , Jacob Schachter 1, 4 and Gal Markel 1, 2, 6 1 Ella Lemelbaum Institute of Immuno-Oncology, Ramat-Gan, Israel 2 Clinical Microbiology and Immunology, Tel-Aviv, Israel 3 Institute of Pathology, Ramat-Gan, Israel 4 School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel 5 Department of Plastic and Reconstructive Surgery, Ramat-Gan, Israel 6 Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel * These authors have contributed equally to this work Correspondence to: Gal Markel, email: Markel@post.tau.ac.il Keywords: melanoma, ICAM-1, adhesion, progression Received: April 12, 2017 Accepted: July 11, 2017 Published: September 14, 2017 ABSTRACT Intercellular adhesion molecule 1 (ICAM-1) protein is an important adhesion molecule that facilitates metastasis on one hand, and on the other hand supports the immunological synapse necessary for T-cell mediated elimination. The expression pattern of ICAM-1 in melanoma was studied more than two decades ago, mainly in cell lines or in unmatched melanoma specimens. By using real time PCR we could not demonstrate a clear difference in ICAM-1 mRNA levels between primary melanocytes and primary cultures of metastatic melanoma. However, immunohistochemistry staining of progression tissue microarray comprised of samples of different disease stages derived from different patients, demonstrated a dramatic ICAM-1 upregulation particularly upon the transition from primary tumor to lymph node metastasis. There was no significant difference between lymph node and distant metastases. Importantly, these results were confirmed in an independent tissue microarray comprised of patient-paired specimens from progressive stages of the patient’s disease. These data indicate that ICAM-1 upregulation is required to initiate the lymphatic spread of melanoma (Stage III) but no further increase is associated with progression to remote organs (Stage IV).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Galore-Haskel et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: